Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 7Carcinoma, Renal Cell 6Neoplasm Metastasis 4Carcinoma, Transitional Cell 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Glioblastoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Basal Cell 2Vulvar Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sjogren's Syndrome 1Seminoma 1Scleroderma, Systemic 1Sarcoma 1Rectal Neoplasms 1

Interventions

selpercatinib 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × CTLA-4 Antigen × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡